Ankylosing Spondylitis Clinical Trials

24-Week trial comparing treatment with Study Medicine vs. placebo. Patient Inclusion Criteria: Age >/= 18 Diagnosis of definite AS Active AS Inadequate response to treatment. Patient Exclusion Criteria: Major Surgery within 8 weeks prior to screening Inflammatory Disease other than AS Treatment with Investigational Medication within 4 weeks Hepatitis B, ...

Do you have Ankylosing Spondylitis? You may qualify to participate in a clinical research study. IL-6Ra mAb is a randomized placebo controlled trial of an injectable IL-6Rmab for patient with active sacroileitis from anklyosing spondylitis with active joint disease who are not responding to NSAIDs and are biologic agent naive. ...

Local doctors are looking for people with Ankylosing Spondylitis (AS) for a clinical research study of an investigational drug. AS is a type of inflammatory arthritis that mostly affects the spine.

Local doctors are looking for people with Ankylosing Spondylitis (AS) for a clinical research study of an investigational drug. AS is a type of inflammatory arthritis that mostly affects the spine.

Axial spondyloarthritis is an inflammatory rheumatic disease mainly affecting joints in the spine and the sacroiliac joints. Inflammatory pathways are likely the central link from axial spondyloarthritis to the known increased risk of atherosclerotic morbidity. Positron emission tomography (PET) is the most sensitive method to detect inflammatory foci in clinical ...

National, prospective, multicentre observational study designed for eligible patients treated with Inflectra. Its objectives are to describe under real conditions of use, the profile of patients treated with Inflectra and the response to treatment.

The objective of this study is to access retention rate, persistence and adherence in population of spondylarthritis (SpA) (ankylosing spondylitis (AS) and psoriatic arthritis (PsA)) participants treated with adalimumab in routine clinical settings in the Russian Federation.

This multcenter, open-label, three period study will evaluate withdrawal and retreatment of etanercept in subjects with nr-ax SpA who achieved adequate response following 24 weeks of treatment.

This is a multi-center, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of ENIA11 in patients with ankylosing spondylitis. The study period for each patient will be 27 weeks, during which the patient will undergo screening for up to 21 days, and followed by treatment of 24 ...

The current study will assess the clinical Assessment of SpondyloArthritis international Society (ASAS) 20 response to Secukinumab and evaluate to which extent concomitant nonsteroidal anti-inflammatory drug (NSAID) treatment can be reduced between Week 4 and Week 12 in patients treated with Secukinumab 150 mg or placebo following an initial run-in ...